Results of a phase 1, randomized study evaluating the effects of food and diurnal variation on the pharmacokinetics of linifanib

Cancer Chemotherapy and Pharmacology

Volumn 74, Issue 1, 2014, Pages 55-61

  Xiong, Hao ^a   Chiu, Yi Lin ^a   Ricker, Justin L ^a   LoRusso, Patricia ^b  

^a ABBVIE INC   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

Bioavailability; Diurnal variation; Food effect; PK; TKIs

Indexed keywords

LINIFANIB;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BACKACHE; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DECREASED APPETITE; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG INDUCED HEADACHE; DYSPHONIA; DYSPNEA; EVENING DOSAGE; FATIGUE; FEMALE; FOOD; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOTHYROIDISM; MALE; NAUSEA; OPEN STUDY; OROPHARYNX PAIN; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STOMATITIS; THORAX PAIN; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; CIRCADIAN RHYTHM; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; FOOD-DRUG INTERACTIONS; HALF-LIFE; HAND-FOOT SYNDROME; HUMANS; HYPERTENSION; INDAZOLES; MALE; NEOPLASMS; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SEVERITY OF ILLNESS INDEX;

EID: 84903818292     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2475-z     Document Type: Article

References (29)

1. Comoglio PM, Di Renzo MF, Gaudino G (1987) Protein tyrosine kinases associated with human malignancies. Ann N Y Acad Sci 511:256-261 (Pubitemid 18093048)
2. Yancopoulos GD et al (2000) Vascular-specific growth factors and blood vessel formation. Nature 407(6801):242-248
3. Carmeliet P et al (1996) Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380(6573):435-439 (Pubitemid 26102719)
4. Gerber HP, Dixit V, Ferrara N (1998) Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem 273(21):13313-13316 (Pubitemid 28246905)
5. Benjamin LE et al (1999) Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 103(2):159-165 (Pubitemid 29053133)
6. Andrae J, Gallini R, Betsholtz C (2008) Role of platelet-derived growth factors in physiology and medicine. Genes Dev 22(10):1276-1312 (Pubitemid 351717519)
7. Jechlinger M et al (2006) Autocrine PDGFR signaling promotes mammary cancer metastasis. J Clin Invest 116(6):1561-1570
8. Cao R et al (2004) PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. Cancer Cell 6(4):333-345 (Pubitemid 39361435)
9. Berger DP et al (1995) Vascular endothelial growth factor (VEGF) mRNA expression in human tumor models of different histologies. Ann Oncol 6(8):817-825
10. Baka S, Clamp AR, Jayson GC (2006) A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis. Expert Opin Ther Targ 10(6):867-876 (Pubitemid 44816749)
11. Zhang T et al (2005) Overexpression of platelet-derived growth factor receptor alpha in endothelial cells of hepatocellular carcinoma associated with high metastatic potential. Clin Cancer Res 11(24 Pt 1):8557-8563 (Pubitemid 43005900)
12. Albert DH et al (2006) Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther 5(4):995-1006 (Pubitemid 43724600)
13. Singh BN (1999) Effects of food on clinical pharmacokinetics. Clin Pharmacokinet 37(3):213-255
14. Ingwersen SH, Mant TG, Larsen JJ (1993) Food intake increases the relative oral bioavailability of vanoxerine. Br J Clin Pharmacol 35(3):308-310 (Pubitemid 23074059)
15. Dresser GK, Spence JD, Bailey DG (2000) Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 38(1):41-57 (Pubitemid 30055093)
16. Musiek ES, Fitzgerald GA (2013) Molecular clocks in pharmacology. Handb Exp Pharmacol 217:243-260
17. Stearns AT et al (2008) Diurnal rhythmicity in the transcription of jejunal drug transporters. J Pharmacol Sci 108(1):144-148
18. Labrecque G, Belanger PM (1991) Biological rhythms in the absorption, distribution, metabolism and excretion of drugs. Pharmacol Ther 52(1):95-107
19. Peng B et al (2004) Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion. J Clin Pharmacol 44(2):158-162 (Pubitemid 38114314)
20. Sparano BA et al (2009) Effect of antacid on imatinib absorption. Cancer Chemother Pharmacol 63(3):525-528
21. Tanaka C et al (2010) Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib. Clin Pharmacol Ther 87(2):197-203
22. Koch KM et al (2009) Effects of food on the relative bioavailability of lapatinib in cancer patients. J Clin Oncol 27(8):1191-1196
23. Klumpen HJ et al (2011) Moving towards dose individualization of tyrosine kinase inhibitors. Cancer Treat Rev 37(4):251-260
24. Food and Drug Administration (2002) Guidance for industry: food-effect bioavailability and fed bioequivalence studies, December 2002
25. Wu S et al (2008) Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol 9(2):117-123
26. Zhu X, Stergiopoulos K, Wu S (2009) Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol 48(1):9-17
27. Ranpura V et al (2010) Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens 23(5):460-468
28. Toh HC et al (2013) Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma. Cancer 119(2):380-387
29. Tannir NM et al (2011) Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure. Eur J Cancer 47(18):2706-2714